Exosomes are secreted by all cell types and contain proteins and nucleic acids. Here, we report that breast cancer associated exosomes contain microRNAs (miRNAs) associated with the RISC-Loading Complex (RLC) and display cell-independent capacity to process precursor microRNAs (pre-miRNAs) into mature miRNAs. Pre-miRNAs, along with Dicer, AGO2, and TRBP, are present in exosomes of cancer cells. CD43 mediates the accumulation of Dicer specifically in cancer exosomes. Cancer exosomes mediate an efficient and rapid silencing of mRNAs to reprogram the target cell transcriptome. Exosomes derived from cells and sera of patients with breast cancer instigate nontumorigenic epithelial cells to form tumors in a Dicer-dependent manner. These findings offer opportunities for the development of exosomes based biomarkers and therapies.
INTRODUCTION
Exosomes are nano-vesicles of 50-140 nm in size that contain proteins, mRNA, and microRNAs (miRNAs) protected by a lipid bilayer (Kahlert and Kalluri, 2013; Cocucci et al., 2009; Simons and Raposo, 2009; Simpson et al., 2008; Thé ry et al., 2002) . Several recent studies demonstrated that exosomes are secreted by multiple cell types, including cancer cells, stem cells, immune cells, and neurons (Thé ry, 2011) . Exosomes levels in the serum of breast cancer patients are generally higher when compared to normal subjects (Logozzi et al., 2009; Taylor and Gercel-Taylor, 2008; O'Brien et al., 2013) . miRNAs are small noncoding RNAs of 18-24 nucleotides (nt) in length that control gene expression posttranscriptionally. They are synthesized via sequential actions of Drosha and Dicer endonucleases, and incorporate with the RNA induced silencing complex (RISC) to target mRNAs (Bartel, 2009; Maniataki and Mourelatos, 2005) . RISC-loaded miRNAs bind in a sequence-specific manner to target mRNAs, initiating their repression through a combination of translational inhibition, RNA destabilization, or through direct RISC-mediated mRNA cleavage (Ambros, 2004; Bartel, 2009; Filipowicz, 2005) . For a miRNA to be functional and achieve efficient gene silencing, it must form a complex with the RISC-loading complex (RLC) proteins Dicer, TRBP,
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Breast cancer cells secrete exosomes with specific capacity for cell-independent miRNA biogenesis, while normal cellderived exosomes lack this ability. Exosomes derived from cancer cells and serum from patients with breast cancer contain the RISC loading complex proteins, Dicer, TRBP, and AGO2, which process pre-miRNAs into mature miRNAs. Cancer exosomes alter the transcriptome of target cells in a Dicer-dependent manner, which stimulate nontumorigenic epithelial cells to form tumors. This study identifies a mechanism whereby cancer cells impart an oncogenic field effect by manipulating the surrounding cells via exosomes. Presence of Dicer in exosomes may serve as biomarker for detection of cancer. and AGO2. Within the RLC, Dicer and TRBP process precursor miRNAs (pre-miRNAs) after they emerge from the nucleus via exportin-5, to generate miRNAs and associate with AGO2. AGO2 bound to the mature miRNA constitutes the minimal RISC and may subsequently dissociate from Dicer and TRBP Gregory et al., 2005; Haase et al., 2005; MacRae et al., 2008; Maniataki and Mourelatos, 2005; Melo et al., 2009) . Single-stranded miRNAs by themselves incorporate into RISC very poorly and therefore cannot be efficiently directed to target mRNAs for posttranscriptional regulation (Tang, 2005; Thomson et al., 2013) . Nonetheless, several reports suggest that miRNAs contained in exosomes can influence gene expression in target cells (Ismail et al., 2013; Kogure et al., 2011; Kosaka et al., 2013; Narayanan et al., 2013; Pegtel et al., 2010; Valadi et al., 2007; Zhang et al., 2010) . Drosha and Dicer are present in exosomes from cell culture supernatants from HIV-1 infected cells and HIV patient sera (Narayanan et al., 2013) . Cofractionation of Dicer, TRBP, and AGO2 in late endosome/ multivesicular bodies (MVBs) is also observed (Shen et al., 2013) . These studies reflect the need to evaluate the functional contribution of miRNA machinery proteins in exosomes and their role in tumor progression.
RESULTS

Isolation and Identification of Exosomes
Exosomes from cancer cells (MDA-MB-231 triple negative human metastatic breast carcinoma, MCF7 human breast adenocarcinoma, 67NR mouse nonmetastatic mammary carcinoma, and 4T1 mouse metastatic mammary carcinoma) and control cells (MCF10A nontumorigenic human mammary epithelial cells and NMuMG nontumorigenic mouse mammary epithelial cells) were isolated using established ultracentrifugation methods (Figure S1A available online; see Supplemental Experimental Procedures) (Luga et al., 2012; Thé ry et al., 2006) . The harvested exosomes were analyzed by transmission electron microscopy (TEM) and atomic force microscopy (AFM). Particles between 50-140 nm were identified (Figures 1A and 1B) (Thé ry et al., 2002) . The average size observed in 112 captured images by TEM was 108 ± 6 nm and by AFM was 112 ± 5 nm (Figures 1A and 1B, graphs) . The identity of the exosomes was confirmed through detection of TSG101, CD9, and CD63, three exosomes markers ( Figure S1B ) (Thé ry et al., 2006) . The isolated exosomes were also positive for the CD9 marker by immunogold TEM (Figure 1A , lower right panel). Exosomes coupled to latex beads were analyzed by flow cytometry, showing expression of CD9, flotillin1, CD63, and TSG101, the commonly used exosomes markers ( Figure S1C ). Light scattering spectroscopy (LSS) Itzkan et al., 2007) was used to show that the isolated samples reveal a tight size distribution with a mode value peaking at 104 nm ( Figure S1D ). LSS also excluded potential microvesicles and bacterial or cellular debris contamination ( Figure S1D ). In agreement with LSS data, the NanoSight nanoparticle tracking analysis for MCF10A, MCF7, MDA-MB-231, 67NR, 4T1, and NMuMG exosomes revealed an average of the mode value of 103 ± 5 nm ( Figure S1E ). Based on LSS and NanoSight analysis, the most prevalent population of particles in solution ranged in size from 89 to 118 nm in diameter (Figures S1D and S1E) . Colorimetric cell viability assay (Thiazolyl blue tetrazolium bromide [MTT] ), terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay, flow cytometry analysis for Anexin V using propidium iodide, and cytochrome C immunoblots (Figures S1F-S1I) were used to demonstrate the viability of cells prior to exosomes extraction to exclude apoptotic bodies or random cell debris. Exosomes isolated from cancer cells are collectively termed as cancer exosomes, whereas exosomes isolated from control cells are collectively termed normosomes.
Cancer Exosomes Are Specifically Enriched in MicroRNAs
The global miRNA content of cancer exosomes and normosomes was investigated. A low correlation between the levels of expression of miRNAs in normosomes and cancer exosomes was observed (MCF10A versus MCF-7:r = 0.56; MCF10A versus MDA-MB-231:r = 0.39; and NMuMG versus 4T1:r = 0.40) (Figure 1C) , while correlation levels among normosomes and among cancer exosomes was generally higher despite their species qPCR data represented are the result of three independent experiments each with three replicates and are represented as ±SEM. Significance was determined using t tests (*p < 0.05). See also Figure S1 and Tables S1, S2 , S3, S4, S5, and S6.
Cancer Cell Figure S2B ). We used a cell-free culture system to determine the expression of miRNAs in exosomes at different time points of culture. Purified exosomes were placed in fetal bovine serum (FBS)-depleted culture media and incubated for 24 and 72 hr at 37 C (see Supplemental Experimental Procedures for details). After the incubation period, exosomes were profiled by miRNA expression arrays ( Figures 1D and 1E ). Cancer exosomes cultured for 72 hr showed an enrichment of miRNAs when compared to cancer exosomes cultured for 24 hr ( Figure 1D ; Tables S4, S5, and S6). On the contrary, normosomes did not show significant differences in miRNAs expression after 72 hr of culture (MCF10A:r = 0.9145; NMuMG:r = 0.9327; MCF7:r = 0.5782; MDA-MB-231:r = 0.5087; and 4T1:r = 0.4833; Figure 1E ).
As proof of concept, a set of miRNAs (miR-10a, miR-10b, miR-21, miR-27a, miR-155, and miR-373) that were increased in cancer exosomes after 72h of culture were used for further analysis ( Figure 1E ). This set was selected because they were significantly upregulated after 72 hr of culture, and each has been extensively implicated in cancer progression ( Figure S2C ; see color-coded miRNAs in scatterplots; Tables S4, S5, and S6). A striking upregulation of the six analyzed miRNAs was observed exclusively in cancer exosomes cultured for 72 hr when compared to cancer exosomes cultured for 24 hr, with an average fold-change of 17.6 for MDA-MB-231-derived exosomes, 4.5 for MCF-7-exosomes, and 13.2 for 4T1-derived cancer exosomes. (Figure 1F ). In contrast, the miRNA content of normosomes was not significantly affected over time ( Figure 1F ).
When the miRNA content of MDA-MB-231, MCF-7, and 4T1 cancer exosomes was compared to that of normosomes from MCF10A and NMuMG cells, an enrichment was observed in all six miRNAs in cancer exosomes cultured for 24 hr with an average fold-change of 2.7, 1.7, and 2.0, respectively (Figure S2D) . At the 72 hr time point, an average fold-change of 30, 4.5, and 18.2 was detected in the six miRNAs in MDA-MB231, MCF-7, and 4T1 derived cancer exosomes, respectively, when compared to MCF10A and NMuMG derived normosomes ( Figure S2D ). Northern blots confirmed the upregulation of miR-10b and miR-21 exclusively in cancer exosomes, lending additional support to the miRNA array expression data and the quantitative PCR (qPCR) analyses ( Figure 1G ).
Cancer Exosomes Contain Pre-MicroRNAs, and the Core RNA Induced Silencing Complex-Loading Complex Proteins The data suggested active miRNA biogenesis in exosomes. Therefore, the potential presence of pre-miRNAs in normosomes and cancer exosomes was explored. Cell-free culture of exosomes 24 or 72 hr after their isolation was performed, and the exosomes subjected to RNase treatment for the depletion of any possible extra-exosomal RNA. This was followed by the detection of the six pre-miRNAs in the exosomes corresponding to the mature miRNAs previously evaluated ( Figure S2E ).
All six pre-miRNAs analyzed were present in exosomes (normosomes and cancer exosomes) (Figures 2A and S2E) . A significant downregulation of pre-miRNAs was observed in cancer exosomes cultured for 72 hr when compared to cancer exosomes cultured for 24 hr. No variation of pre-miRNAs was observed in normosomes ( Figure 2B ). Downregulation of pre-miRNAs in cancer exosomes was further confirmed by northern blot for premiR10b and pre-miR21 ( Figure 2C ). Next, a time-course analysis of pre-miRNAs and miRNAs in exosomes was performed. We cultured isolated cancer exosomes for 6, 12, 24, 36, 48, 72, and 96 hr and observed that the levels of the six pre-miRNAs were inversely proportional to their respective miRNAs ( Figure 2D ). Mature miRNAs increased in quantity between 24 and 72 hr of culture, after which they reached a plateau ( Figure 2D ).
To understand why the processing of pre-miRNAs in cultured exosomes is delayed by 24 hr, we monitored miR-21 and miR-155 in MDA-MB-231 cells that were silenced for exportin-5 (XPO5) ( Figure S2F ). XPO5 is responsible for the transport of pre-miRNAs from the nucleus to the cytoplasm (Yi et al., 2003; Melo et al., 2010) . Silencing XPO5 prevents the flow of premiRNAs from the nucleus to the cytoplasm, allowing for an evaluation of cytoplasmic pre-miRNA processing (Figures S2F and S2G) . miRNA-21 and -155 were monitored in MDA-MB231siXPO5 cells before and after centrifugation ( Figure S2G ), which occurred at 4 C for 3 hr to mimic the conditions of exosomes isolation (see Supplemental Experimental Procedures). Both miR-21 and miR-155 present a lag phase of processing in centrifuged cells ( Figure S2G ). For the cells to accomplish a 2-fold increase of miR-21, 8 hr are enough, while centrifuged cells take about 24 hr for the same fold increase ( Figure S2G ). The same holds true for mir-155 that takes about 10 hr to reach 2-fold increase, while centrifuged cells take 27 hr for the same fold increase ( Figure S2G ). Therefore, exosomes require a certain period of acclimatization that is already expected for recovery of enzymatic activities in cultured cells after tissue culture passage.
miRNA biogenesis requires key protein components of the RLC, Dicer, TRBP, and AGO2 . Dicer and TRBP form a complex that stabilizes Dicer, while AGO2 is recruited later in the biogenesis pathway for strand selection and the RNA unwinding process . Dicer was detected in exosomes derived from MCF7, MDA-MB231, 67NR, and 4T1 cells ( Figures 3A, 3B , and S3A). All exosomes preparations were treated with proteinase K before exosomal protein extraction, as previously described (Montecalvo et al., 2012) (Figures 3A, 3B , and S3A). Dicer was not detected in normosomes produced by MCF10A and NMuMG cells (Figures 3A and S3A) . Immunogold labeling of exosomes using TEM confirmed that Dicer was present in cancer exosomes, but not in normosomes (Figures 3B and S3B) . The use of an anti-GFP antibody as negative control failed to detect any gold particles by immunogold TEM ( Figure S3C ).
Dicer was overexpressed with an N-terminal FLAG tag in MCF10A and MDA-MB-231 cells ( Figure S3D ). Immunoblot and confocal microscopy localized the FLAG-Dicer protein specifically to cancer exosomes ( Figures 3C, S3D , and S3E). In addition, Dicer expression was decreased via stable expression of two short-hairpin constructs in MCF10A and MDA-MB-231 cells ( Figures S3F and S3G ). Exosomes derived from MDA-MB231shDicer cells contained significantly less Dicer compared The data presented are the result of three independent experiments each with three replicates and are represented as ±SEM; significance was determined using t tests (*p < 0.05). Northern blots were performed once to validate qPCR and miRNAs array data. See also Figure S2 .
to shScramble or parental MDA-MB-231 cells, as determined by immunoblot and immunogold TEM ( Figures 3D and 3E ). Dicer was not detected in normosomes derived from MCF10AshDicer cells ( Figure 3D ). RLC proteins, AGO2, and TRBP, were also present in cancer exosomes, but not in normosomes ( Figures 3F and 3G ). Exosomes were extracted from MCF10A and MDA-MB-231 cells transfected with a GFP-tagged AGO2 ( Figure 3H ). The presence of GFP-AGO2 was detected in exosomes extracted from MDA-MB-231-GFP-AGO2 cells (Figure 3I ). Dicer immunoprecipitation revealed that AGO2 binds to Dicer in cancer exosomes, while both are undetectable in normosomes ( Figure 3J ). TRBP functions as a key partner of Dicer protein and aids in its stability and in its pre-miRNA cleavage activity Melo et al., 2009) . Dicer immunoprecipitation revealed the presence of Dicer/TRBP complex in cancer exosomes, but not in normosomes ( Figure 3K ).
MVBs are cellular organelles that contain endosomes that are released as exosomes upon fusion with the plasma membrane (Pant et al., 2012) . We compared the cellular distribution of Dicer together with markers of MVBs. Hrs and BiG2 are early endosome markers, and TSG101 is a marker for MVBs (Razi and Futter, 2006; Shin et al., 2004) . Dicer colocalized with Hrs, BiG2, and TSG101 in MDA-MB231 and 4T1 cells ( Figure S3H ).
Exogenously delivered N-rhodamine-labeled phosphotidylethanolamine (NRhPE) is taken up by cells and retained within MVBs (Sherer et al., 2003) . Dicer labeling in MDA-MB-231 cells colocalized with NRhPE in MVBs ( Figure S3H ). This data is in agreement with previous observations that showed Dicer, TRBP, and AGO2 in late endosomes/MVB fractions using cofractionation analysis (Shen et al., 2013) . In contrast, there was no colocalization of Dicer with Hrs, BiG2, TSG101, or NRhPE in MCF10A cells (Figure S3H) . Further, HRS, TSG101, and BIG2 genes were silenced using two different siRNAs and shRNAs in MDA-MB-231 and MCF10A cells, and Dicer protein expression was evaluated (Figure S3I ). Silencing HRS, BIG2, and TSG101 impaired MVBs formation and led to significant downregulation of exosomes production ( Figure S3J ). Increased Dicer protein was observed in the nucleus and cytoplasm, including MVBs, of MDA-MB-231 cells with siHRS, shBIG2, or siTSG101 ( Figure S3K) . Silencing of HRS, BIG2, or TSG101 genes in MCF10A cells did not alter Dicer protein expression or cellular localization ( Figure S3K) .
Recently, a variety of plasma membrane anchor proteins, such as CD43, were speculated as likely mediators of protein transport into MVBs and exosomes (Shen et al., 2011) . CD43 is predominantly a leukocyte transmembrane sialoglycoprotein, which is aberrantly expressed highly in the cytoplasm of breast cancer cells, but not in normal epithelial cells (Tuccillo et al., 2014) . CD43 is also detected in many solid tumors including breast cancer and correlates with cancer progression and metastasis (Tuccillo et al., 2014) . We demonstrate that Dicer immunoprecipitates with CD43 in MDA-MB231 cells ( Figure 4A ). When CD43 is silenced using siRNA in MCF10A and MDA-MB231 cells, Dicer levels significantly decrease in cancer exosomes and reveal an increased nuclear and cytoplasmic accumulation of Dicer protein ( Figures 4B and 4C ). When CD43 is overexpressed in MCF10A cells (MCF10A-CD43 cells), Dicer is detected in normosomes ( Figure 4D ).
Cancer Exosomes Process Pre-MicroRNAs to Generate Mature MicroRNAs
Next, we examined the ability of RLC proteins in cancer exosomes to generate mature miRNA. Exosomes with suppressed Dicer levels were extracted from the MCF10AshDicer, MDA-MB-231shDicer, and 4T1shDicer cells ( Figure S4A ). The capacity to generate exosomes was not altered upon Dicer downregulation in cells ( Figure S4B ). Dicer-suppressed exosomes did not show any significant changes in pre-miRNAs and miRNAs content at 24 and 72 hr of culture ( Figures S4C and S4D) . Next, anti-Dicer and anti-TRBP antibodies were delivered into cancer exosomes by electroporation and compared to cancer exosomes and normosomes electroporated with an anti-actin control antibody. The exosomes were treated with proteinase K after electroporation to eliminate the possibility of antibodies associated with outer surface of exosomes ( Figure 4E ). Cancer exosomes electroporated with the control anti-actin antibody showed the same variations in pre-miRNA and miRNA levels as previously mentioned (Figures 4F and 4G ). However, in cancer exosomes with anti-Dicer and anti-TRBP antibody, insignificant changes in the levels of pre-miRNA and miRNA were observed with time, suggesting an inhibition of pre-miRNA processing ( Figures 4F and 4G ). Total miRNA content was also assessed by miRNA expression array analysis of MDA-MB-231 exosomes (MDA231 Exos), anti-Dicer antibody electroporated MDA-MB-231 exosomes (MDA231 Exos Dicer antibody [AB]), MDA231 shDicer Exos, MCF10AshDicer Exos, and MCF10A Exos after 72 hr of cell-free culture ( Figure 4H ). The total miRNA content of cancer exosomes with anti-Dicer antibody more closely resembled MCF10A normosomes (r = 0.94) when compared to cancer exosomes (r = 0.67) ( Figure 4H ). When comparing cancer exosomes with cancer exosomes containing anti-Dicer antibody, 198 differentially expressed miRNAs were observed, 48% of which were significantly downregulated (Table S7) . Further data mining showed that 19% of miRNAs were oncogenic, while only 1% possessed tumor-suppressive properties ( Figure S4E ; Table S7 ).
To further confirm the specific pre-miRNA processing capability of cancer exosomes, synthetic pre-miRNAs-10b and -21, as well as the C. elegans precursor pre-cel-1 pre-miRNA, were electroporated into exosomes ( Figure S5A ). We observed significant downregulation of the pre-miRNAs and upregulation of their respective miRNAs in cancer exosomes after 72 hr culture ( Figures 5A and 5B) . Cancer exosomes derived from shDicer cells did not reveal a difference in pre-miRNA content after 72 hr culture ( Figure 5A ). Additionally, pre-miR-10b, -21, and -cel-1 were internally labeled with biotin-deoxythymidine (dT). The dT-modified pre-miRNAs were processed into mature miRNAs when transfected into MCF10A cells (Figures S5B and  S5C) . The modified pre-miRNAs were used in ''dicing'' assays to show that Dicer-containing cancer exosomes were specifically capable of processing pre-miRNA and generate miRNAs ( Figures 5C-5E ).
Cancer Exosomes Induce Tumor Formation in a Dicer-Dependent Manner MDA-MB-231 cells were transfected with CD63-GFP, an exosomes marker (Escola et al., 1998) . MDA-MB-231 cells with CD63-GFP were used to isolate GFP + cancer exosomes, which were subsequently incubated with MCF10A cells. Fluorescence NanoSight detected green exosomes from MDA-MB231-CD63-GFP cells ( Figure S6A ). The green CD63-GFP + cancer exosomes entered MCF10A cells and localized in the cytoplasm (Figure S6B ). Using miRNA expression arrays, we show that MCF10A cells coincubated with MDA-MB-231-derived cancer exosomes acquire a distinct miRNA expression profile (Figure 6A ). mRNA expression profiling reveals pronounced global transcriptome changes in MCF10A cells treated with cancer exosomes compared to MCF10A cells treated with cancer exosomes with Dicer antibody (MCF10A cells + MDA-MB-231 Exos Dicer AB; Figure 6B) . A cross-comparison analysis of the miRNA and mRNA expression profiles of MCF10A cells exposed to MDA-MB-231 cancer exosomes and parental MCF10A cells revealed a correlation between 108 of the upregulated miRNAs and a downregulation of their mRNA targets ( Figures 6A and 6B ). For example, miRNA-21 and -10b were upregulated (4.6-and 2.3-fold, respectively) in cancer exosomes-treated MCF10A cells. miRNA-21 and -10b have been implicated in breast cancer progression and metastasis (Ma et al., 2007; Yan et al., 2011) . As shown earlier, miR-21 and -10b are synthesized in cancer exosomes from their pre-miRNAs ( Figures 1F, 1G, 2C , and 2D). PTEN and HOXD10 are known targets for miR-21 and miR-10b, respectively, and both genes were suppressed in the expression array analysis of MCF10A cells treated with cancer exosomes when compared to control MCF10A cells ( Figure 6B ). Immunoblots of PTEN and HOXD10 showed they were suppressed in MCF10A cells exposed to cancer exosomes ( Figures 6C and  6D 
Cancer Cell
Exosomes and MicroRNA Biogenesis functional delivery of miRNAs from cancer exosomes to recipient cells ( Figure 6E ). PTEN and HOXD10 protein levels were evaluated in MCF10A cells incubated with cancer exosomes at different time points. A significant decrease was detected in PTEN and HOXD10 protein immediately after treating the cells with 72 hr cultured cancer exosomes ( Figures 6C and 6D ). PTEN and HOXD10 protein levels changed minimally in MCF10A cells treated with freshly isolated cancer exosomes, suggesting that sufficient concentration of the mature miRNAs is not present at this time point (Figures S6C and S6D ). MCF10A cells treated with 72 hr-cultured cancer exosomes with Dicer antibody revealed an insignificant downregulation of PTEN and HOXD10 ( Figure 6F ). Additionally, processing of miR-15 in cells, a miRNA not detected in MDA-MB231-derived cancer exosomes, was not altered due to treatment of MCF10A cells with MDA-MB-231 exosomes containing Dicer antibody ( Figure S6E ). Some reports show downregulation of miRNA targets in cells incubated with exosomes without a need for culture (Kosaka et al., 2013; Narayanan et al., 2013; Pegtel et al., 2010) . MiR-182-5p is one of the miRNAs upregulated in MCF10A cells upon cancer exosomes incubation. SMAD4, a miR-182-5p target (Hirata et al., 2012) , is one of the genes downregulated upon cancer exosomes treatment of MCF10A cells ( Figure S6F ). Upregulation of miR-182-5p in cancer exosomes during the culture period was not observed and pre-miR182-5p was not detected in cancer exosomes ( Figure S6G ). Therefore, cancer exosomes also pack mature miRNAs without the need for processing pre-miRs. If such mature miRs are present in stoichiometric amounts, they may be able to regulate gene expression of recipient cells, as shown previously (Ismail et al., 2013; Kogure et al., 2011; Kosaka et al., 2013; Narayanan et al., 2013; Pegtel et al., 2010; Valadi et al., 2007; Zhang et al., 2010) . Cell viability and proliferation of MCF10A cells treated with 72 hr cultured cancer exosomes was increased, which was not observed when freshly isolated cancer exosomes were used ( Figure 6G ). No changes were seen after incubation of MCF10A cells with cancer exosomes containing Dicer antibodies (Figure 6G) . The same held true for the colony formation capacity of MCF10A cells treated with cancer exosomes ( Figure 6H ).
To address the functional ''oncogenic potential'' of MCF10A and MCF10A cells with prior exposure to cancer exosomes (MCF10A cells + MDA231 exos culture), we implanted the cells into the mammary fat pads of female nu/nu mice. Similar to results previously published, MCF10A cells did not form tumors in nude mice (Mavel et al., 2002; Thé ry et al., 2002) (Figure 6I ). MCF10A cells coinjected with cancer exosomes formed tumors, whereas MCF10A cells coinjected with cancer exosomes containing Dicer antibody (but not control anti-actin antibodies) showed a significant reduction in tumor growth (Figures 6I and S6H) . These results suggest that Dicer in cancer exosomes contributes to oncogenic conversion of MCF10A cells (Figures 6G-6I ).
Serum Exosomes from Cancer Patients Contain Dicer and Process Pre-MicroRNAs to Generate Mature MicroRNAs
Freshly isolated human primary ovarian, breast, and endometrial tumor fragments were orthotopically grafted onto the appropriate organs of female athymic nu/nu mice ( Figures S7A and  S7B) , and serum exosomes from these mice were evaluated by TEM ( Figure S7C ). Size exclusion immunoblot of the exosomes extracts demonstrated the existence of Dicer exclusively of human origin in the purified exosomes (hsa-Dicer) ( Figures 7A  and S7D ). Protein extracts from 4T1-derived exosomes were used as controls to show that Dicer of mouse origin exhibited a different molecular size (mmu-Dicer) ( Figure 7A ). Additionally, serum exosomes from nude mice orthotopically injected with MDA-MB-231 cells or MCF10A cells show Dicer protein of human origin in MDA-MB-231-injected mice, while no protein is detected in serum exosomes of MCF10A-injected mice or noninjected mice ( Figure 7B ). This strongly supports the fact that Dicer in exosomes is exclusively originated from the human cancer epithelial cells injected into mice.
Next, 100 ml of fresh serum samples were used to isolate exosomes from eight healthy individuals (H) and 11 patients with breast carcinoma (BC) ( Figure 7C ). Exosomes were 100 nm (average of the mode for the size distributions), and their lipid bilayer membranes were identified by TEM (Figures 7C and  7D ). Serum of breast cancer patients contained significantly more exosomes when compared to serum of healthy donors ( Figure 7E ). When equal numbers of exosomes were placed in culture for 24 and 72 hr, the six pre-miRNAs (vide supra) were found to be downregulated exclusively in breast cancer patients, and their respective mature miRNAs were upregulated after 72 hr of culture ( Figures 7F and 7G) . Next, exosomes alone or combined with MCF10A cells were injected orthotopically in the mammary fat pad of female nu/nu mice. We noted that five out of 11 serum exosomes induced MCF10A cells to form tumors ( Figure 7H ). In contrast, when exosomes from healthy donors were combined with MCF10A cells or administered alone, tumors were not detected ( Figure 7H ). Interestingly, exosomes that formed tumors were also shown to have the highest increase in the amount of mature miRNAs after 72 hr culture ( Figures 7F  and 7G ). Exosomes from serum of breast cancer patients and healthy donors were analyzed for Dicer expression. Dicer protein (F) MDA-MB-231 exosomes were harvested in quadruplicate. Samples were electroporated with anti-Dicer, antiactin, or anti-TRBP antibodies. The three samples plus control were left in cell-free culture conditions (FBS-depleted) for 24 and 72 hr. After 24 and 72 hr exosomes were extracted, and the six pre-miRNAs were quantified by qPCR. The fold-change of each pre-miRNA in exosomes after 72 hr cell-free culture was quantified relative to the same pre-miRNA in exosomes after 24 hr cell-free culture in each sample. The graphical plots represent the fold change of the six pre-miRNAs. (G) MDA-MB-231 exosomes were harvested in quadruplicate. Samples were electroporated with anti-Dicer, antiactin, or anti-TRBP antibodies. The three samples plus control were left in cell-free culture conditions (FBS-depleted) for 24 and 72 hr. After 24 and 72 hr exosomes were extracted once again, and the six miRNAs were quantified by qPCR. The fold-change of each miRNA in exosomes after 72 hr cell-free culture was quantified relative to the same miRNA in exosomes after 24 hr cell-free culture in each sample. The graphical plots are a representation of the fold change of the six miRNAs. (H) HeatMap of miRNAs array MDA-MB-231 exos, exosomes electroporated with Dicer antibody (MDA231 exos Dicer AB), MCF10A exosomes, MDA-MB-231 shDicer Exosomes, and MCF10AshDicer Exosomes. An average of duplicates is represented for each sample. The qPCR data are the result of three independent experiments each with three replicates and are represented as ±SEM; significance was determined using t tests (*p < 0.05). See also Figure S4 and Table S7 . , and MCF-7shDicer (MCF7 shDicer electroporated) cells. Exosomes were recovered after cell-free culture conditions (FBS-depleted) for 72 hr. Pre-miR-10b, -21, and -cel-1 were quantified by qPCR before and after 72 hr of electroporation and culture. The plots represent the fold-change of pre-miR-10b, -21, and -cel-1 72 hr after electroporation relative to 24 hr after electroporation. (B) Synthetic pre-miRNAs-10b, -21, and -cel-1 were electroporated into exosomes harvested from the same cells as in (A) . Exosomes were recovered after cellfree culture conditions (FBS-depleted) for 72 hr. MiR-10b, -21, and -cel-1 were quantified by qPCR before and after 72 hr of electroporation and culture. Plots represent the fold-change of miR-10b, -21, and -cel-1 72 hr after electroporation relative to 24 hr after electroporation. (C) Northern blot without detection probe, using samples from dicing assay. Synthetic pre-miR-10b internally labeled with biotin was used for the dicing assay. Samples used were MCF10A, MCF10AshDicer, MDA-MB231 exosomes, MDA-MB231shDicer clone1 and clone2 exosomes, MDA-MB231shDicer cells, and MDA-MB231 exosomes electroporated with Dicer antibody. (D) Northern blot without detection probe, using samples from dicing assay. Synthetic pre-miR-21 internally labeled with biotin was used for the dicing assay. Samples used were MCF10A, MCF10AshDicer, MDA-MB231 exosomes, MDA-MB231shDicer clone1 and clone2 exosomes, MDA-MB231shDicer cells, and MDA-MB231 exosomes electroporated with Dicer antibody. (E) Northern blot without detection probe using samples from dicing assay. Synthetic pre-cel-miR-1 internally labeled with biotin was used for the dicing assay. Samples used were the same ones as in (D) . The qPCR data are the result of three independent experiments each with three replicates and are represented as ±SEM. See also Figure S5 .
in exosomes was observed mainly in breast cancer samples that formed tumors in nude mice when coinjected with MCF10A cells and not in exosomes from serum of H ( Figure 7I ).
DISCUSSION
The functional role of miRNAs associated with exosomes in cancer progression is largely unknown. Many studies suggest the presence of miRNAs in exosomes and speculated on their function (Valadi et al., 2007; Zhang et al., 2010) . Given that miRNAs need to be present in a stoichiometric concentration for appropriate silencing of mRNA targets, it seems unlikely that exosomes in circulation would provide sufficient concentrations of mature miRNAs to repress the target transcriptome. The processing of the pre-miRNAs originated from exosomes in the recipient cells is an unlikely event because miRNA biogenesis Δ   BC10  BC2  BC3  BC4  BC5  BC8  BC9  BC6  BC1  BC7  BC11   BC10  BC2  BC3  BC4  BC5  BC8  BC9  BC6  BC1  BC7  BC11 (legend on next page) in recipient cells is rate-limiting not only due to the total amount of pre-miRNAs available for processing in the receiving cell, but also due to rate-limiting amounts of required enzymes. Therefore, it is more efficient to have mature miRNAs entering recipient cells for direct alteration of gene expression posttranscriptionally without having to go through a processing pathway. We demonstrated that inhibiting the action of Dicer in cancer exosomes significantly impairs tumor growth in recipient cells, suggesting that miRNA biogenesis in exosomes contributes to cancer progression. Recent studies show that melanoma-derived exosomes play a role in metastasis (Peinado et al., 2012) . Exosomes derived from fibroblasts play a role in the migration of breast cancer cells (Luga et al., 2012) . Exosomes derived from cancer cells have a protumorigenic role associated with the transfer of mRNA and proangiogenic proteins (Luga et al., 2012; Peinado et al., 2012; Skog et al., 2008) . Exosomes derived from cancer cells can also contribute to a horizontal transfer of oncogenes, such as EGFRvIII (Al-Nedawi et al., 2008) . Our study demonstrates that cancer exosomes mediate significant transcriptome alterations in target cells via RISC-associated miRNAs. A myriad of biological processes in the target cells are affected by exosomes that induce proliferation and have the potential to convert nontumorigenic cells into tumor-forming cells. Nonetheless, the potential in vivo effect of cancer exosomes on recipient cells likely depends on several other environmental parameters and accessibility barriers. Collectively, this study unravels the possible role cancer exosomes play in inducing an oncogenic ''field effect'' that further subjugates adjacent normal cells to participate in cancer development and progression. This study does not indicate that such field effect is systemic; therefore additional studies may be required to address such implications.
EXPERIMENTAL PROCEDURES
Exosomes were purified from cells cultured in exosomes-depleted FBS, using sequential centrifugations to discard dead cells and cellular debris. All exosomes samples were subjected to a PBS washing step followed by ultracentrifugation. This was followed by filtration of the supernatant with 0.2 mm filters and ultracentrifugation for 2 hr, as previously described (Li et al., 2012; Luga et al., 2012) . Exosomes used for RNA extraction were treated with Proteinase K and RNase prior to lysis of exosomes. Exosomes for protein extraction were treated with Proteinase K and Urea/SDS lysis buffer.
Human Samples
Human serum samples were obtained from the MD Anderson Cancer Center (MDACC) through appropriate informed consents after approval by the institutional review board (IRB). The IRB protocol numbers are, 04-0657 and 04-0698. The primary tumor specimens were obtained at the Hospital Universitari de Bellvitge (L'Hospitalet de Llobregat, Barcelona, Spain). The IRB approved the study. Written informed consent was collected from patients (see Supplemental Experimental Procedures).
Animal Studies
All mice were housed under standard housing conditions at the Beth Israel Deaconess Medical Center (BIDMC), MDACC, and IDIBELL animal facilities. All animal procedures were reviewed and approved by the BIDMC, MDACC, and the Spanish Institutional Animal Care and Use Committees (see Supplemental Experimental Procedures).
Statistical Analysis
Error bars indicate ±SEM between biological replicates. Technical as well as biological triplicates of each experiment were performed. Statistical significance was determined using t tests, except for multiple-group comparisons, for which significance was determined using one-way ANOVA with Tukey post hoc analysis with GraphPad Prism (GraphPad Software). A p value < 0.05 was considered statistically significant. Pearson correlation coefficient (r value) was calculated assuming linear relationship between variables.
Detailed descriptions of all the methods used in the manuscript are listed in the Supplemental Experimental Procedures file. 
